Tags

Type your tag names separated by a space and hit enter

Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal beta(2)-agonist.
Pulm Pharmacol Ther. 2007; 20(6):701-7.PP

Abstract

BACKGROUND

A combination of bronchodilators may be effective in the treatment of chronic obstructive pulmonary disease (COPD). We examined the effect of adding a long-acting anti-cholinergic agent (tiotropium) to a transdermal-type beta(2)-agonist (tulobuterol) on dyspnea as well as pulmonary function.

METHODS

In a multicentre, randomized, parallel design study, 60 COPD patients treated with the transdermal beta(2)-agonist tulobuterol were divided into a tiotropium added group (Tulo+Tio group, n=40) or transdermal beta(2)-agonist tulobuterol alone group (Tulo group, n=20), and then treated for 4 weeks after a 2 week run-in period. Pulmonary function and a dyspnea (Medical Research Council (MRC)) scale were assessed before and after the treatment. Daily peak expiratory flow (PEF) monitoring was also performed.

RESULTS

After 4 weeks, the Tulo+Tio group showed a significant increase in pulmonary function compared with the Tulo group; DeltaFVC (0.31+/-0.06 L vs. 0.06+/-0.05 L, p< 0.01), DeltaFEV(1) (0.15+/-0.03 L vs. -0.02+/-0.02 L, p<0.0001), and DeltaPEF (41.0+/-5.1 L/min vs. 0.5+/-3.5 L/min, p<0.0001). The MRC dyspnea scale was also significantly improved in Tulo+Tio, but not in Tulo group.

CONCLUSION

These results suggest that tiotropium caused a significant improvement in both pulmonary function and dyspnea in COPD patients already treated with the transdermal beta(2)-agonist tulobuterol.

Authors+Show Affiliations

Third Department of Internal Medicine, Wakayama Medical University, School of Medicine, 811-1 Kimiidera, Wakayama 641-8509, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17049894

Citation

Akamatsu, K, et al. "Improvement of Pulmonary Function and Dyspnea By Tiotropium in COPD Patients Using a Transdermal Beta(2)-agonist." Pulmonary Pharmacology & Therapeutics, vol. 20, no. 6, 2007, pp. 701-7.
Akamatsu K, Yamagata T, Takahashi T, et al. Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal beta(2)-agonist. Pulm Pharmacol Ther. 2007;20(6):701-7.
Akamatsu, K., Yamagata, T., Takahashi, T., Miura, K., Maeda, S., Yamagata, Y., Ichikawa, T., Yanagisawa, S., Ueshima, K., Hirano, T., Nakanishi, M., Matsunaga, K., Minakata, Y., & Ichinose, M. (2007). Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal beta(2)-agonist. Pulmonary Pharmacology & Therapeutics, 20(6), 701-7.
Akamatsu K, et al. Improvement of Pulmonary Function and Dyspnea By Tiotropium in COPD Patients Using a Transdermal Beta(2)-agonist. Pulm Pharmacol Ther. 2007;20(6):701-7. PubMed PMID: 17049894.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal beta(2)-agonist. AU - Akamatsu,K, AU - Yamagata,T, AU - Takahashi,T, AU - Miura,K, AU - Maeda,S, AU - Yamagata,Y, AU - Ichikawa,T, AU - Yanagisawa,S, AU - Ueshima,K, AU - Hirano,T, AU - Nakanishi,M, AU - Matsunaga,K, AU - Minakata,Y, AU - Ichinose,M, Y1 - 2006/09/14/ PY - 2006/05/29/received PY - 2006/08/21/revised PY - 2006/08/29/accepted PY - 2006/10/20/pubmed PY - 2008/1/30/medline PY - 2006/10/20/entrez SP - 701 EP - 7 JF - Pulmonary pharmacology & therapeutics JO - Pulm Pharmacol Ther VL - 20 IS - 6 N2 - BACKGROUND: A combination of bronchodilators may be effective in the treatment of chronic obstructive pulmonary disease (COPD). We examined the effect of adding a long-acting anti-cholinergic agent (tiotropium) to a transdermal-type beta(2)-agonist (tulobuterol) on dyspnea as well as pulmonary function. METHODS: In a multicentre, randomized, parallel design study, 60 COPD patients treated with the transdermal beta(2)-agonist tulobuterol were divided into a tiotropium added group (Tulo+Tio group, n=40) or transdermal beta(2)-agonist tulobuterol alone group (Tulo group, n=20), and then treated for 4 weeks after a 2 week run-in period. Pulmonary function and a dyspnea (Medical Research Council (MRC)) scale were assessed before and after the treatment. Daily peak expiratory flow (PEF) monitoring was also performed. RESULTS: After 4 weeks, the Tulo+Tio group showed a significant increase in pulmonary function compared with the Tulo group; DeltaFVC (0.31+/-0.06 L vs. 0.06+/-0.05 L, p< 0.01), DeltaFEV(1) (0.15+/-0.03 L vs. -0.02+/-0.02 L, p<0.0001), and DeltaPEF (41.0+/-5.1 L/min vs. 0.5+/-3.5 L/min, p<0.0001). The MRC dyspnea scale was also significantly improved in Tulo+Tio, but not in Tulo group. CONCLUSION: These results suggest that tiotropium caused a significant improvement in both pulmonary function and dyspnea in COPD patients already treated with the transdermal beta(2)-agonist tulobuterol. SN - 1094-5539 UR - https://www.unboundmedicine.com/medline/citation/17049894/Improvement_of_pulmonary_function_and_dyspnea_by_tiotropium_in_COPD_patients_using_a_transdermal_beta_2__agonist_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1094-5539(06)00092-7 DB - PRIME DP - Unbound Medicine ER -